← back to search

Silvia Gasperoni

European Society for Medical Oncology ·
Area of research
Pulmonary and Respiratory Medicine · Gastroenterology
Research interest
Research interests include Gastrointestinal Tumor Research and Treatment, Gastric Cancer Management and Outcomes, Sarcoma Diagnosis and Treatment, and Colorectal Cancer Treatments and Studies.
h-index
23
citations
6,423
works
95
NIH funding
primary concept
Medicine
email

Recent publications

How Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis
European Journal of Cardio-Thoracic Surgery 2026cited by 0position: middledoi
Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective study
JTCVS Open 2025cited by 1position: middledoi
<sup>18</sup>F-Fluorodeoxyglucose Uptake in <i>PDGFRA</i>-Mutant Gastrointestinal Stromal Tumors
JAMA Network Open 2025cited by 0position: middledoi
Outcome of Patients with Curative-Intent Treatment for Primary Pulmonary Sarcoma: Results of an International Multicenter Database
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie 2025cited by 0position: middledoi
How should Primary Pulmonary Sarcoma be staged? Results of an International Multicenter Database
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie 2025cited by 0position: middledoi
<i>KIT/PDGFRA</i> Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study
The Oncologist 2023cited by 6position: middledoi
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence
JAMA Network Open 2023cited by 5position: middledoi
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Annals of Oncology 2021cited by 955position: middledoi
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 2021cited by 550position: middledoi
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology 2021cited by 439position: middledoi
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Clinical Cancer Research 2021cited by 43position: middledoi
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study
ESMO Open 2021cited by 15position: middledoi
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors (GIST): A retrospective, multicenter, real-world study.
Journal of Clinical Oncology 2021cited by 0position: middledoi
Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
ESMO Open 2020cited by 22position: middledoi
Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).
Journal of Clinical Oncology 2020cited by 0position: firstdoi
Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.
Journal of Clinical Oncology 2020cited by 0position: middledoi
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).
Journal of Clinical Oncology 2019cited by 0position: firstdoi
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 2018cited by 1,615position: middledoi
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 2018cited by 751position: middledoi
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 2018cited by 633position: middledoi
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
Therapeutic Advances in Medical Oncology 2018cited by 33position: middledoi
FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.
Journal of Clinical Oncology 2018cited by 1position: middledoi
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
Therapeutic Advances in Medical Oncology 2017cited by 24position: middledoi
Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.
Journal of Clinical Oncology 2017cited by 1position: middledoi
Rechallenge in GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey
Annals of Oncology 2017cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Bruno Vincenzi · Università Campus Bio-Medico16 papers (2017–2025) · 13 papers (2017–2025) · 12 papers (2017–2025)Giovanni Grignani · Hospital Universitario Fundación Jiménez Díaz11 papers (2017–2025)Maria A. Pantaleo · Instituto Nazionale Tumori Regina Elena10 papers (2017–2025)Elena Fumagalli · Fondazione IRCCS Istituto Nazionale dei Tumori10 papers (2017–2023) · 9 papers (2017–2025)Antonella Brunello · Hospital Universitario Fundación Jiménez Díaz9 papers (2018–2026) · 8 papers (2017–2025)Angelo Paolo Dei Tos · University of Padua6 papers (2017–2020)Giuseppe Tonini · Campus Bio Medico University Hospital6 papers (2017–2020)Alessandro Mazzocca · Università Campus Bio-Medico5 papers (2019–2023)Daniele Santini · Azienda Ospedaliera Sant'Andrea5 papers (2017–2020)Andrea Napolitano · Università Campus Bio-Medico4 papers (2018–2020)Luigi Cerbone · Azienda Sanitaria Locale Alessandria4 papers (2025–2026) · 4 papers (2025–2026) · 4 papers (2025–2026) · 4 papers (2017–2025)Paolo G. Casali · Fondazione IRCCS Istituto Nazionale dei Tumori4 papers (2017–2018)Sarah Watson · University of California System4 papers (2025–2026)